Back to Search Start Over

Advancing Cancer Therapy Predictions with Patient-Derived Organoid Models of Metastatic Breast Cancer.

Authors :
Önder, Cansu E.
Ziegler, Teresa J.
Becker, Ronja
Brucker, Sara Y.
Hartkopf, Andreas D.
Engler, Tobias
Koch, André
Source :
Cancers; Jul2023, Vol. 15 Issue 14, p3602, 13p
Publication Year :
2023

Abstract

Simple Summary: A frequent disabling symptom during metastasized breast cancer is the development of ascites and pleural effusion, which is associated with poor outcomes. Malignant cells in ascites and pleural effusions derived from the primary tumor site indicate the spreading of cancer and can serve as a model for metastatic breast cancer. Therefore, we cultured metastatic cells from six patients with ascites or pleural effusion in a three-dimensional fashion to obtain organoids. The organoids recapitulated the characteristics of metastatic samples, as shown by immunohistochemistry and mutation analysis. Drug assays of organoids were performed to assess individual responses in a personalized manner. Overall, metastatic organoid cultures derived from malignant pleural effusion and malignant ascites demonstrated in vivo-like phenotypes and drug responses. Hence, these metastatic organoids can serve as an accurate model for the investigation of breast cancer progression and therapy predictions. The poor outcome of metastasized breast cancer (BC) stresses the need for reliable personalized oncology and the significance of models recapitulating the heterogeneous nature of BC. Here, we cultured metastatic tumor cells derived from advanced BC patients with malignant ascites (MA) or malignant pleural effusion (MPE) using organoid technology. We identified the characteristics of tumor organoids by applying immunohistochemistry and mutation analysis. Tumor organoids preserved their expression patterns and hotspot mutations when compared to their original metastatic counterpart and are consequently a well-suited in vitro model for metastasized BC. We treated the tumor organoids to implement a reliable application for drug screenings of metastasized cells. Drug assays revealed that responses are not always in accord with expression patterns, pathway activation, and hotspot mutations. The discrepancy between characterization and functional testing underlines the relevance of linking IHC stainings and mutational analysis of metastasized BC with in vitro drug assays. Our metastatic BC organoids recapitulate the characteristics of their original sample derived from MA and MPE and serve as an invaluable tool that can be utilized in a preclinical setting for guiding therapy decisions. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
20726694
Volume :
15
Issue :
14
Database :
Complementary Index
Journal :
Cancers
Publication Type :
Academic Journal
Accession number :
168601695
Full Text :
https://doi.org/10.3390/cancers15143602